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A B S T R A C T
Rubinstein-Taybi syndrome (RSTS) is a neurodevelopmental disorder characterized by growth retardation,
skeletal anomalies and intellectual disability, caused by heterozygous mutation in either the CREBBP (RSTS1) or
EP300 (RSTS2) genes. We generated an induced pluripotent stem cell line from an RSTS2 patient's blood
mononuclear cells by Sendai virus non integrative reprogramming method. The iPSC line (IAIi001RSTS2-65-A)
displayed iPSC morphology, expressed pluripotency markers, possessed trilineage diﬀerentiation potential and
was stable by karyotyping. Mutation and western blot analyses demonstrated in IAIi001RSTS2-65-A the patient's
speciﬁc non sense mutation in exon 23 c.3829A > T, p.(Lys 1277*) and showed reduced quantity of wild type
p300 protein.
Resource table
Unique stem cell line
identiﬁer
IAIi001-A
Alternative name(s) of
stem cell line
IAIi001RSTS2-65-A
Institution Istituto Auxologico Italiano (IAI)-IRCCS,
Milan, Italy
Contact information of
distributor
Lidia Larizza, l.larizza@auxologico.it
Type of cell line iPSC
Origin Human
Additional origin info Age: 25 years
Sex: male
Ethnicity: Caucasian
Cell source
Peripheral blood mononuclear cells
(PBMCs)
Clonality Clonal
Method of
reprogramming
Sendai virus
Genetic modiﬁcation N/A
Type of modiﬁcation Spontaneous mutation
Associated disease Rubinstein-Taybi syndrome type 2 (RSTS2)
Gene/locus EP300 gene c.3829A > T, p.(Lys1277*)
Method of
modiﬁcation
N/A
Name of transgene or
resistance
N/A
Inducible/constitutive
system
N/A
Date archived/stock
date
March 2017
N/A
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T
Cell line repository/
bank
Ethical approval The study was approved by the ethical
committee (CE) of Istituto Auxologico
Italiano (IAI). CE code: 2015_12_15_02
Peripheral blood draw was obtained after
informed consent was given.
Resource utility
This is the ﬁrst iPSC line created for Rubinstein-Taybi syndrome. It
provides a tool to disclose novel pathomechanisms downstream of
mutation of EP300 chromatin modiﬁer gene and to identify biomarkers
for epigenetic therapeutics of this rare neurodevelopmental disorder.
Resource details
Rubinstein-Taybi Syndrome (RSTS) is a rare multiple congenital
Fig. 1. Characterization of Rubinstein-Taybi syndrome type 2 induced pluripotent stem cell line (IAIi001-A).
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anomalies and intellectual disability syndrome characterized by growth
retardation, skeletal anomalies and cognitive impairment, mainly
caused by de novo heterozygous mutation in either CREBBP or EP300
genes, encoding the homologous acetyltransferases and transcriptional
coactivators CBP and p300 (Roelfsema and Peters, 2007). RSTS type 2
which clinical presentation is overall milder than RSTS1 (Fergelot et al.,
2016) results from inactivating EP300 mutations leading to p300 pro-
tein either reduced in quantity or defective in enzymatic function.
Following institutional ethical committee approval and patient in-
formed consent, peripheral blood was withdrawn from a 25-year-old
male with RSTS2, who was previously clinically and molecularly de-
scribed (Negri et al., 2016). Induced pluripotent stem cells (iPSCs) were
generated from peripheral blood mononuclear cells (PBMCs) (Soares
et al., 2015) using integration-free Sendai virus particles transducing
target cells with replication-competent RNAs encoding the four repro-
gramming Yamanaka factors (Fusaki et al., 2009). iPSCs were grown on
irradiated Mouse Embryonic Fibroblasts (MEFs) feeder layers. After
21 days from transduction iPSC colonies were manually selected and
culture expanded. The iPSC line described here was named
IAIi001RSTS2-65-A and was characterized by evaluating distinctive
iPSC morphology and expression of the pluripotency markers by im-
munocytochemistry and FACS analyses (SSEA4, OCT3/4, TRA-1-60,
Fig. 1A, 99% SSEA4+cells, 85% TRA-1-60+ cells, Fig. 1B) and potential
to diﬀerentiate along ectodermal, mesodermal and endodermal lineages
(NESTIN, αSMA and SOX17, Fig. 1C). Cytogenetic analysis, performed
on> 30 mitoses, showed that the IAIi001RSTS2–65-A iPSC line was
karyotypically normal at P6 (Fig. 1D). Sanger sequencing, performed on
DNA extracted from IAIi001RSTS2–65-A revealed the EP300 exon 23
non sense mutation c.3829A > T, (p.(Lys1277*)) (Fig. 1E). Western
blot analysis showed a 40% reduced quantity of the full length p300
protein observed (band> 250 KDa) in control cells (Fig. 1F).
Materials and methods
Reprogramming of RSTS2 patient's erythroblasts to iPSCs
Following informed consent PBMCs were collected via gradient
centrifugation from an RSTS2 patient with an EP300 mutation
c.3829A > T, (p.(Lys1277*)) and cultured for 9 days in enriched
StemSpan™ Medium (Stemcell Technologies) at 37 °C in 5% CO2.
Reprogramming was performed by Sendai virus (Cytotune 2.0,
LifeTech) (Soares et al., 2015) (Table 1).Transduced cells were plated
on MEF feeders in HESC (human embryonic stem cell) medium (DMEM-
F1220% KOSR, 1mM L-glutamine, 1×NEAA, 4 ng/ml FGF (all re-
agents from Life Technologies) and100mM β-mercaptoethanol
(Sigma))and fed every other day. Colonies were picked at day 20 and
manually passaged weekly by cutting through the single colony in
several places with a sterile syringe needle and then removing the
colony by scraping it. Passage ratio is 1:5.iPSCs were harvested in 60%
HESC medium, 30% FBS and 10% DMSO and stored in liquid nitrogen.
Pluripotency marker immunocytochemistry
IAIi001-RSTS2–65-A were ﬁxed in 4% paraformaldehyde (20min,
37 °C). Antibodies in gelatin dilution buﬀer (0.2% gelatin (for
blocking), 0.3% Triton-×100 (for permeabilization), 20 mM Sodium
Phosphate Buﬀer pH 7.4, 0.45M NaCl, all by Sigma) were incubated at
4 °C overnight (primary) and 2 h at RT (secondary). Nuclei were
counterstained with DAPI. Images were acquired with a Nikon Eclipse
Ti microscope (Table 2).
Flow cytometry
iPSCs were dissociated in PBS/0.5 mM EDTA, ﬁxed using BD
Cytoﬁx™ buﬀer (BD Biosciences) and stained with TRA-1-60 or SSEA4
antibody (both 1 h, 4 °C) followed by the speciﬁc ﬂuorescently tagged
secondary antibody (1 h 4 °C). Antibodies were diluted in 0,1% BSA,
0,5 mM EDTA in 1×PBS solution. Cells were analyzed using a Gallios
(Beckman Coulter) ﬂow cytometer and Kaluza software. An iPSC line
from a healthy donor was used as a characterization control.
In vitro trilineage diﬀerentiation potential assay
iPSCs were cultured on vitronectin-coated chamber slides and dif-
ferentiated using the STEMdiﬀ™ trilineage diﬀerentiation kit (Stemcell
Technologies) according to the manufacturer's instructions (Table 2).
Karyotyping
Chromosomes, prepared at P6, after colcemid (10 μg/ml) overnight
at 37 °C (5% CO2, 95% rH) were incubated in hypotonic solution (KCl
0.56%, 6min, RT), washed 3min with acetic acid 5% and ﬁxed with
methanol/acetic acid (3:1). Q-banded metaphases were photographed
at 100× (Leica microscope and camera) and>30 were karyotyped
using CytoVision software (Leica).
Array-CGH analysis
High-resolution array comparative genomic hybridisation (array-
CGH) was performed on genomic blood and iPSC DNA using the
SurePrint G3 Human CGH Microarray Kit 4x180K in accordance with
the manufacturer's instructions (Agilent Technologies). Data were then
extracted and analyzed for copy number changes using Agilent
CytoGenomics v.3.0.
Table 1
Characterization and validation.
Classiﬁcation Test Result Data
Morphology Photography Normal Fig. 1A
Phenotype Immunocytochemistry Positive for expression of pluripotency markers: SSEA4, OCT3/4, TRA-1-60 Fig. 1A
Flow cytometry Determined cell surface expression of SSEA4 (99%) and TRA-1-60 (85%) Fig. 1B
Genotype Karyotype (Q-banding) and resolution 46XY resolution: 400 band level Fig. 1D
Identity Microsatellite PCR (mPCR) OR STR
analysis
Not performed Available with Authors
CNV analysis Array-CGH detected CNVs (no.10) compared in IAIi001-A versus RSTS2–65A
donor's PBMCs. 100% matching
Mutation analysis Sequencing Conﬁrmed heterozygous non sense mutation in exon 23 of EP300 gene,
c.3829A > T, p.(Lys1277*)
Fig. 1E
Western blot Conﬁrmed reduced quantity (40%) of full length p300 protein Fig. 1F
Microbiology and virology Mycoplasma Negative Supplementary ﬁg. S1
Diﬀerentiation potential Directed diﬀerentiation Determined the expression of markers for each of the three germ layers:
NESTIN, ectoderm; αSMA, mesoderm; SOX17, endoderm
Fig. 1C
V. Alari et al. Stem Cell Research 30 (2018) 175–179
177
Ta
bl
e
2
A
nt
ib
od
ie
s
us
ed
fo
r
im
m
un
oc
yt
oc
he
m
is
tr
y/
ﬂ
ow
-c
it
om
et
ry
.
A
nt
ib
od
ie
s
us
ed
fo
r
im
m
un
oc
yt
oc
he
m
is
tr
y/
ﬂ
ow
-
ci
to
m
et
ry
A
nt
ib
od
y
D
ilu
ti
on
C
om
pa
ny
C
at
#
an
d
R
R
ID
Pl
ur
ip
ot
en
cy
m
ar
ke
rs
R
ab
bi
t
an
ti
-O
C
T3
/4
1:
20
0
(I
F)
Sa
nt
a
C
ru
z
Bi
ot
ec
hn
ol
og
y
C
at
#
sc
-9
08
1,
R
R
ID
:A
B_
21
67
70
3
Pl
ur
ip
ot
en
cy
m
ar
ke
rs
M
ou
se
an
ti
-T
R
A
-1
-6
0
1:
10
0
(I
F)
Sa
nt
a
C
ru
z
Bi
ot
ec
hn
ol
og
y
C
at
#
sc
-2
1,
70
5,
R
R
ID
:A
B_
62
83
85
Pl
ur
ip
ot
en
cy
m
ar
ke
rs
M
ou
se
an
ti
-S
SE
A
4
1:
10
0
(I
F)
Th
er
m
o
Fi
sh
er
Sc
ie
nt
iﬁ
c
C
at
#
14
–8
84
3-
80
,
R
R
ID
:A
B_
65
78
47
Pl
ur
ip
ot
en
cy
m
ar
ke
rs
M
ou
se
an
ti
-S
SE
A
4
1:
10
0
(F
A
C
S)
A
bc
am
C
at
#
ab
16
28
7,
R
R
ID
:A
B_
77
80
73
Pl
ur
ip
ot
en
cy
m
ar
ke
rs
M
ou
se
an
ti
-T
R
A
-1
-6
0
1:
10
0
(F
A
C
S)
A
bc
am
C
at
#
ab
16
28
8,
R
R
ID
:
A
B_
A
B_
77
85
63
D
iﬀ
er
en
ti
at
io
n
m
ar
ke
rs
(D
M
)
M
ou
se
an
ti
-N
ES
TI
N
1:
10
0
St
em
ce
ll
Te
ch
no
lo
gi
es
C
at
#
60
,0
91
C
E,
R
R
ID
:A
B_
26
50
58
1
D
iﬀ
er
en
ti
at
io
n
m
ar
ke
rs
(D
M
)
R
ab
bi
t
an
ti
-S
O
X
17
1:
20
0
C
el
l
Si
gn
al
in
g
In
c.
C
at
#
81
77
8,
R
R
ID
:A
B_
26
50
58
2
D
iﬀ
er
en
ti
at
io
n
m
ar
ke
rs
(D
M
)
M
ou
se
an
ti
-α
SM
A
1:
20
0
M
ill
ip
or
e
C
at
#
C
BL
17
1,
R
R
ID
:A
B_
22
23
16
6
W
es
te
rn
im
m
un
ob
lo
t
R
ab
bi
t
po
ly
cl
on
al
an
ti
-p
30
0
1:
30
0
Sa
nt
a
C
ru
z,
N
-1
5
C
at
#
sc
58
4,
R
R
ID
:A
B
22
93
42
9
W
es
te
rn
im
m
un
ob
lo
t
M
ou
se
m
on
oc
lo
na
l
an
ti
-a
ct
in
an
ti
bo
dy
1:
20
00
Si
gm
a,
A
C
40
,C
at
#
A
38
53
,R
R
ID
:A
B
26
21
37
Se
co
nd
ar
y
an
ti
bo
di
es
A
nt
i-
ra
bb
it
IG
-H
R
P
1:
20
00
M
ill
ip
or
e
C
at
#
A
P3
07
P,
R
R
ID
:
A
B
92
64
1
Se
co
nd
ar
y
an
ti
bo
di
es
A
nt
i-
m
ou
se
Ig
G
-H
R
P
1:
20
00
M
ill
ip
or
e,
C
at
#
A
P1
24
P,
R
R
ID
:
A
B
90
45
6
Se
co
nd
ar
y
an
ti
bo
di
es
F(
ab
’)
2-
G
oa
t
an
ti
-
R
ab
bi
t
Ig
G
(H
+
L)
,
A
le
xa
®F
lu
or
55
5
1:
30
0
Th
er
m
o
Fi
sh
er
Sc
ie
nt
iﬁ
c
C
at
#
A
-2
14
30
,
R
R
ID
:A
B_
25
35
85
1
Se
co
nd
ar
y
an
ti
bo
di
es
A
nt
i-
m
ou
se
Ig
G
,
A
le
xa
®F
lu
or
48
8
1:
50
0
Th
er
m
o
Fi
sh
er
Sc
ie
nt
iﬁ
c
C
at
#
A
-1
10
01
,
R
R
ID
:A
B_
25
34
06
9
Se
co
nd
ar
y
an
ti
bo
di
es
A
nt
i-
m
ou
se
Ig
G
,
A
le
xa
®F
lu
or
48
8
1:
40
0
(f
or
SS
EA
4)
Th
er
m
o
Fi
sh
er
Sc
ie
nt
iﬁ
c
C
at
#
A
11
05
9,
R
R
ID
:A
B_
25
34
10
6
Se
co
nd
ar
y
an
ti
bo
di
es
A
nt
i-
ra
bb
it
Ig
G
,A
le
xa
®F
lu
or
48
8
1:
20
0
(f
or
SO
X
17
)
Th
er
m
o
Fi
sh
er
Sc
ie
nt
iﬁ
c
C
at
#
A
11
03
4,
R
R
ID
:A
B_
25
76
21
7
Se
co
nd
ar
y
an
ti
bo
di
es
A
nt
i-
m
ou
se
Ig
M
,A
le
xa
®F
lu
or
48
8
1:
20
0
(f
or
TR
A
-1
-
60
)
Th
er
m
o
Fi
sh
er
Sc
ie
nt
iﬁ
c
C
at
#
A
21
04
2,
R
R
ID
:A
B_
A
B_
25
35
71
1
Se
co
nd
ar
y
an
ti
bo
di
es
A
nt
i-
m
ou
se
Ig
G
2a
C
ro
ss
-a
ds
or
be
d
Se
co
nd
ar
y
an
ti
bo
dy
,A
le
xa
®F
lu
or
63
3
1:
20
0
(f
or
αS
M
A
)
Th
er
m
o
Fi
sh
er
Sc
ie
nt
iﬁ
c
C
at
#
A
-2
11
36
,
R
R
ID
:A
B_
25
35
77
5
Pr
im
er
s
Ta
rg
et
Fo
rw
ar
d/
re
ve
rs
e
pr
im
er
(5
′-3
′)
Ta
rg
et
ed
m
ut
at
io
n
an
al
ys
is
/s
eq
ue
nc
in
g
EP
30
0_
Ex
23
c.
38
29
A
>
T
F:
A
TG
C
C
C
TT
C
A
TG
TT
TC
TT
C
A
TG
TC
R
:T
G
C
A
TT
C
TA
C
A
A
A
TC
C
G
TT
C
C
TT
G
V. Alari et al. Stem Cell Research 30 (2018) 175–179
178
EP300 mutation analysis by sanger sequencing
Genomic DNA was extracted using QIAmp DNA Mini kit (Qiagen).
EP300 exon 23 was ampliﬁed with GoTaq Flexi DNA polymerase
(Promega) using exon ﬂanking primers (95 °C-58 °C-72 °C, 35 cycles).
Direct sequencing used the Big Dye Terminator v.1.1 Cycle Sequencing
kit and ABI Prism 3130 Sequencer (Applied Biosystem).
Electropherograms were analyzed with ChromasPro software 2.1.5
(Technelysium Pty Ltd). Sequence ENSG00000100393 was the EP300
reference.
Western blot
Cells grown on vitronectin were detached with ReLeSR™ (Stemcell
Technologies), pelleted and lysed in ice-cold 50mM Tris-HCl
(pH 7.4),150mM NaCl, 0.5% Igepal, 1 mM EDTA, 1mM DTT, 1mM
PMSF, 0.2 mM Na3VO4, protease and phosphatase inhibitors cocktail
(Sigma/Aldrich). Nuclear proteins were released with DNase I (20 U) in
20mM Tris-HCl (pH 7.4) 2.5mM MgCl2, 20mM NaCl, and 1mM PMSF
(20min, 4 °C) mixed with the soluble fraction in SDS-loading buﬀer and
boiled (70 ͦC 10min). Proteins (120 μg) were separated on NuPAGE
4–12% Bis-Tris Gel (Invitrogen), transferred to nitrocellulose and
blocked with 5% BSA in PBS-0.2% Tween 20 (PBS-T). The membrane
was incubated (1 h, RT) with antibodies to p300 and actin, and with
HRP-labelled secondary antibodies (30min, RT) (Table 2). Chemilu-
minescence signals were revealed with a Westar R imager (Hi-Tech
Cyanagen). ImageJ was used for densitometric analyses.
Mycoplasma test
We ruled out the presence of Mycoplasma by using EZ-PCR
Mycoplasma Test Kit (Biological Industries) according to the manu-
facturer's instructions. Positive Control was included in the kit.
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.scr.2018.06.009.
Acknowledgements
The Authors wish to thank the patient and his family for partici-
pation in this study and the Italian Association for Rubinstein-Taybi
“Una vita Speciale” for cooperation. This work was supported by Italian
Ministry of Health ERA-NET NEURON JTC2015 “Chromisyn” (to L.L.)
References
Fergelot, P., Van Belzen, M., Van Gils, J., Afenjar, A., Armour, C.M., Arveiler, B., Beets, L.,
Burglen, L., Busa, T., Collet, M., Deforges, J., de Vries, B.B., Dominguez Garrido, E.,
Dorison, N., Dupont, J., Francannet, C., Garciá-Minaúr, S., Gabau Vila, E., Gebre-
Medhin, S., Gener Querol, B., Geneviève, D., Gérard, M., Gervasini, C.G., Goldenberg,
A., Josifova, D., Lachlan, K., Maas, S., Maranda, B., Moilanen, J.S., Nordgren, A.,
Parent, P., Rankin, J., Reardon, W., Rio, M., Roume, J., Shaw, A., Smigiel, R., Sojo, A.,
Solomon, B., Stembalska, A., Stumpel, C., Suarez, F., Terhal, P., Thomas, S., Touraine,
R., Verloes, A., Vincent-Delorme, C., Wincent, J., Peters, D.J., Bartsch, O., Larizza, L.,
Lacombe, D., Hennekam, R.C., 2016. Phenotype and genotype in 52 patients with
Rubinstein-Taybi syndrome caused by EP300 mutations. Am. J. Med. Genet. A 170
(12), 3069–3082. http://dx.doi.org/10.1002/ajmg.a.37940.
Fusaki, B., Ban, H., Nishiyama, A., Saeki, K., Hasegawa, M., 2009. Eﬃcient induction of
transgene-free human pluripotent stem cells using a vector based on Sendai virus, an
RNA virus that does not integrate into the host genome. Proc. Jpn. Acad. Ser B Phys.
Biol. Sci. 85, 348–362.
Negri, G., Magini, P., Milani, D., Colapietro, P., Rusconi, D., Scarano, E., Bonati, M.T.,
Priolo, M., Crippa, M., Mazzanti, L., Wischmeijer, A., Tamburrino, F., Pippucci, T.,
Finelli, P., Larizza, L., Gervasini, C., 2016. From whole gene deletion to point mu-
tations of EP300-positive Rubinstein-Taybi patients: new insights into the mutational
Spectrum and peculiar clinical hallmarks. Hum. Mutat. 37 (2), 175–183. http://dx.
doi.org/10.1002/humu.22922.
Roelfsema, J.H., Peters, D.J., 2007. 2007. Rubinstein-Taybi syndrome: clinical and mo-
lecular overview. Expert Rev. Mol. Med. 9 (23), 1–16. http://dx.doi.org/10.1017/
S1462399407000415.
Soares, F.A.C., Pedersen, Roger A., Vallier, L., 2015. Generation of human induced
pluripotent stem cells from peripheral blood mononuclear cells using Sendai virus.
Methods Mol. Biol. http://dx.doi.org/10.1007/7651_2015_202.
V. Alari et al. Stem Cell Research 30 (2018) 175–179
179
